

Amendments to the Specification

Please replace the paragraph at page 4, lines 17-27 with the following paragraph:

In some embodiments, the invention provides a polypeptide selected from the group consisting of AAAFTGLTLEQLLDLSDNAQLR (SEQ ID NO: 26); LDLSDNAQLR (SEQ ID NO: 27); LDLSDDAELR (SEQ ID NO: 29); LDLASDNAQLR (SEQ ID NO: 30); LDLASDDAELR (SEQ ID NO: 31); LDALSDNAQLR (SEQ ID NO: 32); LDALSSDDAELR (SEQ ID NO: 33); LDLSSDNAQLR (SEQ ID NO: 34); LDLSSDEAELR (SEQ ID NO: 35); DNAQLRWDPPT (SEQ ID NO: 36); DNAQLR (SEQ ID NO: 37); ADLSDNAQLRWDPPT (SEQ ID NO: 41); LALSDNAQLRWDPPT (SEQ ID NO: 42); LDLSDNAALRWDPPT (SEQ ID NO: 43); LDLSDNAQLHWDPTT (SEQ ID NO: 44); and LDLSDNAQLAVVDPTT (SEQ ID NO: 45).

Please replace the paragraph at page 53, lines 12-20 with the following paragraph:

The 7E11 binding site was further analyzed by testing trypsic peptide digests of sNgR310. HPLC analyses showed several fragments, indicating that there were several trypsin-sensitive lysine and arginine residues in the NgR1 sequence. 7E11 bound only a single tryptic digest peptide, providing additional evidence that 7E11 binds to a single epitope on NgR1. Subsequent mass spectroscopy (MS) and sequence analyses identified the bound peptide to be AAAFTGLTLEQLLDLSDNAQLR (SEQ ID NO: 26).